Verheyden, S <br/><br/>
A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation.  [electronic resource] 

 -  Leukemia  Aug 2005 
 - 1446-51 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0887-6924 
<br/><br/><label>Standard No.: </label>10.1038/sj.leu.2403839  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Child<br/>Child, Preschool<br/>Female<br/>Genotype<br/>Graft vs Host Disease<br/>Graft vs Leukemia Effect<br/>Hematopoietic Stem Cell Transplantation--methods<br/>Histocompatibility<br/>Histocompatibility Testing<br/>Humans<br/>Keratin-2<br/>Keratins<br/>Killer Cells, Natural--immunology<br/>Leukemia--mortality<br/>Leukocyte Transfusion--methods<br/>Male<br/>Middle Aged<br/>Receptors, Immunologic--genetics<br/>Receptors, KIR<br/>Secondary Prevention<br/>Survival Analysis